+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Succeeding in the 2020 POC Drugs of Abuse Testing Market: Supplier Shares and Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

  • PDF Icon

    Report

  • 165 Pages
  • February 2020
  • Region: Global
  • VPG Market Research
  • ID: 4990617

This new 165-page report from the publisher contains 14 tables, and provides a comprehensive analysis of thePOC drugs of abuse testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC abused drugs market.

Rationale

The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.

Market Segmentation Analysis

- Review of three POC market segments, including their dynamics, trends, structure,
size, growth and major suppliers.

- Five-year test volume and reagent sales forecasts for drugs of abuse procedures
by market segment:

- Physician Offices/Group Practices
- Emergency Rooms
- Ambulatory Care Centers

- Analysis of drugs of abuse procedures

Competitive Assessments

- Assessments of major POC suppliers and emerging market entrants,
including their sales, product portfolios, marketing tactics, joint ventures,
and new products in R&D.

Strategic Recommendations

- Specific opportunities for new instruments and reagent systems with potentially
significant market appeal during the next five years.
- Design criteria for POC testing products.
- Alternative business expansion strategies.
- Potential market entry barriers and risks.

Methodology

This report is based on a combination of primary and secondary sources of information, including review of the latest technical and business publications, manufacturer product literature, industry analyst reports, and the publisher's proprietary data files.

Contains 165 pages and 14 tables


Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies
  • Beckman Coulter/Danaher
  • bioMerieux
  • Bio-Rad
  • DiaSorin
  • Eiken Chemical
  • Fujirebio
  • Grifols
  • Instrumentation Laboratory/Werfen
  • Kyowa Medex
  • Ortho-Clinical Diagnostics
  • PerkinElmer
  • Quest Diagnostics
  • Roche
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher
  • Tosoh
  • Wako